Journal article
A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma
Blood, Vol.120(11), pp.2290-2296
09/13/2012
DOI: 10.1182/blood-2012-05-430389
PMCID: PMC3447783
PMID: 22740447
Abstract
Biologic factors that predict the survival of patients with a diffuse large B-cell lymphoma, such as cell of origin and stromal signatures, have been discovered by gene expression profiling. We attempted to simulate these gene expression profiling findings and create a new biologic prognostic model based on immunohistochemistry. We studied 199 patients (125 in the training set, 74 in the validation set) with de novo diffuse large B-cell lymphoma treated with rituximab and CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or CHOP-like therapies, and immunohistochemical stains were performed on paraffin-embedded tissue microarrays. In the model, 1 point was awarded for each adverse prognostic factor: nongerminal center B cell–like subtype, SPARC (secreted protein, acidic, and rich in cysteine) < 5%, and microvascular density quartile 4. The model using these 3 biologic markers was highly predictive of overall survival and event-free survival in multivariate analysis after adjusting for the International Prognostic Index in both the training and validation sets. This new model delineates 2 groups of patients, 1 with a low biologic score (0-1) and good survival and the other with a high score (2-3) and poor survival. This new biologic prognostic model could be used with the International Prognostic Index to stratify patients for novel or risk-adapted therapies.
Details
- Title: Subtitle
- A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma
- Creators
- Anamarija M. Perry - University of Nebraska Medical CenterTeresa M. Cardesa-Salzmann - Department of Pathology, Hospital Clinic, University of Barcelona, Barcelona, SpainPaul N. Meyer - University of Nebraska Medical CenterLuis Colomo - Department of Pathology, Hospital Clinic, University of Barcelona, Barcelona, SpainLynette M. Smith - University of Nebraska Medical CenterKai Fu - University of Nebraska Medical CenterTimothy C. Greiner - University of Nebraska Medical CenterJan Delabie - Department of Pathology, The Norwegian Radium Hospital, Oslo, NorwayRandy D. Gascoyne - Department of Pathology, British Columbia Cancer Agency, Vancouver, BCLisa Rimsza - University of Arizona Cancer CenterElaine S. Jaffe - Laboratory of Pathology, National Cancer Institute, National Institute of Health, Bethesda, MDGerman Ott - Robert Bosch (Germany)Andreas Rosenwald - University of WürzburgRita M. Braziel - Oregon Health & Science UniversityRaymond Tubbs - Cleveland ClinicJames R. Cook - Cleveland ClinicLouis M. Staudt - Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MDJoseph M. Connors - Department of Medicine, British Columbia Cancer Agency, Vancouver, BCLaurie H. Sehn - Department of Medicine, British Columbia Cancer Agency, Vancouver, BCJulie M. VoseArmando López-Guillermo - Hematology Department, Hospital Clinic, University of Barcelona, Barcelona, SpainElias Campo - Department of Pathology, Hospital Clinic, University of Barcelona, Barcelona, SpainWing C. Chan - University of Nebraska Medical CenterDennis D. Weisenburger - University of Nebraska Medical Center
- Resource Type
- Journal article
- Publication Details
- Blood, Vol.120(11), pp.2290-2296
- DOI
- 10.1182/blood-2012-05-430389
- PMID
- 22740447
- PMCID
- PMC3447783
- NLM abbreviation
- Blood
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Publisher
- American Society of Hematology
- Number of pages
- 7
- Grant note
- National Institutes of Health
- Language
- English
- Date published
- 09/13/2012
- Academic Unit
- Pathology
- Record Identifier
- 9984822991702771
Metrics
4 Record Views